GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ulixertinib overview

Ulixertinib (BVD-523) is under development for the treatment of metastatic uveal melanoma, metastatic melanoma, non-small cell lung cancer, acute myelogenous leukemia, metastatic colorectal cancer, metastatic pancreatic cancer, myelodysplastic syndromes, esophageal squamous cell carcinoma, adenocarcinoma of the gastroesophageal junction, gastric cancer, pancreatic cancer, extrahepatic bile duct cancer, low grade glioma, oligodendroglioma, neurofibromatosis type 1 and bile duct cancer . The drug candidate is a small molecule and is administered orally. It acts by targeting ERK1 and 2 (Extracellular signal-Regulated Kinases).

It was also under development for metastatic adenocarcinoma of the pancreas.

BioMed Valley Discoveries overview

BioMed Valley Discoveries (BioMed) a subsidiary of Stowers Institute for Medical Research is a clinical stage biotechnology company which develops novel medicines for cancer. The company’s product portfolio includes CNV-NT an injection of clostridium novyi-NT spores to treat solid tumors, BVD-523 for the treatment of metastatic pancreatic cancer. It also provides BVD-723, a gamma inhibitor which counteracts cancer’s evasiveness and help boost an immune response to the disease, CD276 antibody-drug conjugate (ADC) used as a therapeutic agent to target multiple solid tumor. The company is developing therapies in the areas of oncology and immuno-oncology. BioMed is headquatered in Kansas, ?Missouri, the US.

For a complete picture of Ulixertinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.